HC Wainwright Issues Optimistic Forecast for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.41) for the quarter, up from their previous forecast of ($0.65). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.42) EPS.

A number of other research firms also recently issued reports on ZNTL. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Guggenheim decreased their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Wells Fargo & Company cut their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.74 on Monday. Zentalis Pharmaceuticals has a one year low of $1.66 and a one year high of $18.07. The firm has a market cap of $123.99 million, a P/E ratio of -0.70 and a beta of 1.86. The stock’s 50-day moving average is $2.94 and its 200-day moving average is $3.26.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH bought a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000. Capstone Investment Advisors LLC purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after buying an additional 5,333 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.